In the original article, there was a mistake in Figure 1 as published. An entry was labelled as “No adherence” rather than “Disease progression”. The corrected Figure 1 appears below.
Figure 1
In the original article, there was also a mistake in Table 2 as published. Incorrect data appears for Duration of TTFields therapy, months, median (range) and TTFields daily usage ≥75%, n (%) for TTFields plus TMZ. The corrected Table 2 appears below.
Table 2
| Characteristics | TTFields plus TMZ (n=39) | TMZ alone (n=20) | P value* |
|---|---|---|---|
| Age, years, median (range) | 74 (70–83) | 73 (70–80) | 0.186 |
| Sex, n (%) | 0.957 | ||
| Male | 29 (74) | 15 (75) | |
| Female | 10 (26) | 5 (25) | |
| Corticosteroid therapy, n (%) | 12 (31) | 5 (25) | 0.643 |
| Extent of resection, n (%) | 0.312 | ||
| Biopsy | 7 (18) | 1 (5) | |
| Partial resection | 13 (33) | 6 (30) | |
| Gross total resection | 19 (49) | 13 (65) | |
| MGMT tissue available and tested, n (%) | 0.443 | ||
| Methylated | 16 (46) | 4 (27) | |
| Unmethylated | 15 (43) | 9 (60) | |
| Invalid | 4 (11) | 2 (13) | |
| IDH1R132H tissue available and tested, n (%) | 24 (62) | 10 (50) | 0.512 |
| Positive | 1 (4) | 0 (0) | |
| Negative | 23 (96) | 10 (100) | |
| EGFR tissue available and tested, n (%) | 26 (67) | 10 (50) | 0.529 |
| Amplified | 10 (38) | 5 (50) | |
| Not amplified | 16 (62) | 5 (50) | |
| Chromosomes 1p and 19q tissue available and tested, n (%) | 24 (62) | 10 (50) | 0.241 |
| Codeletion | 0 (0) | 0 (0) | |
| Loss 1p only | 0 (0) | 0 (0) | |
| Loss 19q only | 0 (0) | 1 (10) | |
| Retained | 23 (96) | 9 (90) | |
| Invalid | 1 (4) | 0 (0) | |
| KPS,a median (range) | 85 (60–100) | 90 (70–100) | |
| Time from diagnosis to randomization, months, median (range) | 3.7 (2.6–5.1) | 3.9 (2.8–5.4) | 0.268 |
| Time from last day of radiotherapy to randomization, days, median (range) | 35 (23–49) | 42 (29–50) | 0.016 |
| TMZ cycles until first tumor progression, n, median (range) | 6 (1–15) | 6 (1–12) | 0.441 |
| Time from randomization to TTFields initiation, days, median (range) | 5 (1–13) | NA | |
| Duration of TTFields therapy, months, median (range) | 6.9 (0–40) | NA | NA |
| TTFields daily usage ≥75%, n (%) | 19 (41) | NA | NA |
Baseline characteristics in TTFields (200 kHz) plus TMZ combination versus TMZ monotherapy groups for patients ≥70 years of age.
EGFR, epidermal growth factor receptor gene; IDH1R132H, isocitrate dehydrogenase gene 1 R132H mutation site; KPS, Karnofsky Performance Score; MGMT, O6-methylguanine-DNA-methyltransferase gene; n, number of patients; NA, not applicable; TMZ, temozolomide; TTFields, Tumor Treating Fields.
Karnofsky Performance Score is measured from 0 to 100 in 10-point bins. A higher score represents better performance status.
*Chi-squared test for percentage values and T test for means values.
Total percentage sums may not equal 100 or total percent of a patient subpopulation due to rounding to nearest integer.
In the original article, there was a further mistake in Figure 3C as published. There was an error in KPS, median (range) for TTFields (200 kHz) ≥75% Daily Usage. The corrected Figure 3 appears below.
Figure 3
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
elderly patients, newly diagnosed glioblastoma, TTFields, Tumor Treating Fields, phase 3 clinical trial, efficacy and safety, quality-of-life, temozolomide
Citation
Ram Z, Kim C-Y, Hottinger AF, Idbaih A, Nicholas G and Zhu J-J (2022) Corrigendum: Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients With Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial. Front. Oncol. 12:902929. doi: 10.3389/fonc.2022.902929
Received
23 March 2022
Accepted
25 March 2022
Published
12 April 2022
Volume
12 - 2022
Edited and reviewed by
Matthias Preusser, Medical University of Vienna, Austria
Updates
Copyright
© 2022 Ram, Kim, Hottinger, Idbaih, Nicholas and Zhu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zvi Ram, zviram@tasmc.health.gov.il
This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.